Cantor Fitzgerald Maintains Overweight on Arcus Biosciences, Lowers Price Target to $36
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Li Watsek has maintained an Overweight rating on Arcus Biosciences (NYSE:RCUS) but lowered the price target from $46 to $36.
November 08, 2023 | 5:29 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Arcus Biosciences' price target has been lowered from $46 to $36 by Cantor Fitzgerald, though the Overweight rating is maintained.
The lowering of the price target by Cantor Fitzgerald could potentially lead to a negative sentiment among investors, which may put downward pressure on the stock price in the short term. However, the maintained Overweight rating indicates that the analyst still sees potential in the company's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100